HK Stock Market Move | INNOVENT BIO (01801) rose more than 4% in the afternoon, DaBele's key research long-term follow-up data will be released at the AACR annual meeting.

INNOVENT BIO (01801) rose more than 4% in the afternoon, with a 3.73% increase at the time of publication, reaching 86.1 Hong Kong dollars, with a turnover of 625 million Hong Kong dollars. On the news front, according to a message from INNOVENT BIO's official WeChat account, the long-term follow-up data of the new generation of ROS1 tyrosine kinase inhibitor Taletrectinib (also known as Tabrecta) were presented in oral and poster form at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The long-term analysis of data from the TRUST-I and TRUST-II clinical trials showed a median duration of response (mDOR) of nearly 50 months for TKI-naive patients, a median progression-free survival (mPFS) of 46.1 months, and an objective response rate (ORR) of 89.8%. Tabrecta is an oral, potent, centrally active, highly selective new generation ROS1 inhibitor. It has received priority reviews and breakthrough therapy designation from the National Medical Products Administration (NMPA) and the Food and Drug Administration (FDA). It has been approved for marketing in mainland China, Macau, the United States, Japan, and other regions.